Shocking Medical Discovery: Popular Joint Supplement Linked to Faster Aging – What You Need to Know

A study published in the Journal of the American Medical Association (JAMA) on June 22, 2026, suggests that a widely used joint supplement may accelerate the progression of osteoarthritis, prompting calls for reevaluation of its safety profile. The research, conducted by a team at the University of California, San Francisco (UCSF), analyzed data from over 12,000 participants who regularly took glucosamine and chondroitin sulfate, two common ingredients in joint health supplements. The findings, which have not yet been peer-reviewed, indicate a 14% increased risk of cartilage degradation in long-term users compared to non-users.

The study’s lead author, Dr. Emily Torres, emphasized that the results do not confirm causation but highlight a significant association that warrants further investigation. “While these supplements are widely marketed as safe, our data suggest a potential link between prolonged use and worsened joint outcomes,” Torres stated in a press release. The research was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the National Institutes of Health (NIH).

Supplements containing glucosamine and chondroitin are among the most commonly purchased over-the-counter (OTC) products in the United States, with an estimated 11 million adults using them for joint pain relief, according to the Consumer Healthcare Products Association. The findings have raised concerns among rheumatologists, who note that previous clinical trials on these supplements have yielded mixed results. A 2021 meta-analysis published in the British Medical Journal (BMJ) found no significant benefit for osteoarthritis symptoms, though some studies suggested modest improvements in pain reduction.

The JAMA study’s methodology involved a longitudinal analysis of electronic health records from 2015 to 2025, tracking participants’ supplement use and joint health outcomes. Researchers controlled for variables such as age, body mass index (BMI), and pre-existing joint conditions. The observed risk increase was most pronounced in individuals who used the supplements for more than five years. However, the study’s authors acknowledged limitations, including potential confounding factors like unmeasured lifestyle habits and the lack of randomized controlled trial (RCT) data.

Regulatory agencies have yet to issue formal guidance in response to the findings. The U.S. Food and Drug Administration (FDA) classifies glucosamine and chondroitin as dietary supplements, which are not subject to the same rigorous pre-market approval process as prescription medications. “The FDA does not evaluate the safety or efficacy of supplements before they reach the market,” said a spokesperson in a statement. “However, we encourage consumers to consult with healthcare providers before starting any new supplement regimen.”

Public health experts are urging caution, particularly for older adults who are more likely to use these products. Dr. Rajesh Patel, a professor of geriatric medicine at Johns Hopkins University, noted that the study’s results could influence clinical recommendations. “Patients should be aware that while these supplements may provide temporary relief, their long-term effects on joint health remain unclear,” he said. “It’s crucial to balance potential benefits against emerging risks.”

The research has also reignited debates about the regulation of OTC supplements. Critics argue that the lack of standardized dosing and quality control measures increases the risk of adverse effects. In 2023, the European Medicines Agency (EMA) recommended stricter oversight of joint supplements, citing similar concerns about long-term safety. However, the U.S. Congress has not passed legislation to reform supplement regulations, despite repeated calls from consumer advocacy groups.

Consumers are advised to discuss supplement use with their healthcare providers, especially if they have a history of joint issues or are taking other medications. The NIAMS has updated its website to include the new findings, adding a disclaimer that “current evidence does not support a definitive link between these supplements and joint deterioration, but ongoing research is needed.”

Researchers plan to publish a follow-up study in 2027, which will